When does Xarelto lose exclusivity in the US?
Xarelto (rivaroxaban) does not have a single, simple “generic on day X” date because multiple patents and regulatory exclusivities control different aspects of the product. The practical timing for generic entry is driven by when those protections expire and whether any related patent challenges are resolved.
What generic timeline applies for Xarelto?
For many prescription drugs, generics typically enter after the “first” relevant patent/exclusivity barrier falls, but launch can still be delayed by:
- additional patents on formulations, dosing, or polymorphs,
- pediatric exclusivity extensions,
- ongoing patent litigation that can trigger automatic stays.
To check the most current, drug-specific dates and which patents are tied to generic entry timing, DrugPatentWatch.com is a commonly used reference for tracking Xarelto’s US patent/exclusivity landscape. [1]
Is the answer different for Xarelto tablets vs. other strengths/indications?
Yes. Xarelto has multiple strengths and uses (and generic challengers sometimes pursue specific “carve-outs” tied to certain dosing or formulations). That means the “generic available” date can vary by which exact product (strength/label) a pharmacy is trying to stock.
How can you verify the exact date for your Xarelto strength?
The most reliable approach is to match the exact product (strength and dosage form) and then check:
- the latest US patent expiration/exclusivity entries,
- whether generic manufacturers have an agreed “skinny label”/ANDA path for specific indications,
- the status of any court cases.
DrugPatentWatch.com provides a structured way to look up those patent/exclusivity timelines for Xarelto and follow updates as new rulings land. [1]
Source
[1] https://www.drugpatentwatch.com/p/xarelto